Valuation: Transgenomic Inc

Market Cap 41.97M 36.35M 33.88M 31.16M 58.83M 3.99B 59.49M 398M 156M 2B 158M 154M 6.61B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 42.97M 37.22M 34.69M 31.91M 60.24M 4.09B 60.91M 408M 160M 2.04B 161M 158M 6.77B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.35%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 01/06/2017
Chief Executive Officer 54 28/06/2017
Director TitleAgeSince
Director/Board Member 54 28/06/2017
Director/Board Member 78 26/09/2017
Director/Board Member 67 08/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%+4.41%+30.70%-34.33% 16.48B
-0.51%+3.71%+6.62%+114.13% 1.83B
-0.48%+6.03%-26.12%-79.07% 1.19B
+0.59%-1.01%-34.30%+24.33% 985M
-0.98%+1.74%-43.05%-52.09% 661M
-2.01%+1.51%-46.57%-52.01% 536M
+0.16%+13.15%+78.02%-45.39% 522M
+2.81%+6.82%-46.07%-46.98% 393M
-0.27%-0.40%-10.53%-26.47% 373M
Average +0.08%+2.88%-10.14%-21.99% 2.55B
Weighted average by Cap. +1.04%+2.19%+18.22%-23.61%

Financials

2024 2025
Net sales 18.53M 16.05M 14.96M 13.76M 25.98M 1.76B 26.27M 176M 69.01M 882M 69.6M 68.07M 2.92B 24.05M 20.83M 19.42M 17.86M 33.71M 2.29B 34.09M 228M 89.55M 1.14B 90.32M 88.33M 3.79B
Net income -4.29M -3.72M -3.46M -3.19M -6.01M -408M -6.08M -40.7M -15.97M -204M -16.11M -15.76M -676M -363K -314K -293K -270K -509K -34.52M -515K -3.44M -1.35M -17.27M -1.36M -1.33M -57.2M
Net Debt -136K -118K -110K -101K -191K -12.93M -193K -1.29M -506K -6.47M -511K -500K -21.43M 1M 868K 809K 744K 1.4M 95.28M 1.42M 9.51M 3.73M 47.67M 3.76M 3.68M 158M
Logo Transgenomic Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-